Drug Design and Optimization

• Prof Dr Rolf W. Hartmann

  Senior Professor in the Department Drug Design and Optimization

  

  +49 681 98806-2000

  Write E-Mail

  CV and Publications

• Dr Martin Empting

  Habilitant

  

  +49 681 98806-2000

  Write E-Mail

News

• 2023-01-24

  ERC Proof of Concept Grant for Anna Hirsch

  

  The COVID-19 pandemic has highlighted the importance of effective drugs to combat infectious diseases and has led to numerous innovations and developments in antiviral agents. At the same time, however, it may also have provided a significant boost to the spread of antibiotic resistance. This is because many of the patients infected with SARS-CoV-2 were treated with antibiotics as a…

• 2023-01-23

  Disarming pathogens: New drug candidates to combat chronic infections

  

  Although bacteria are among the simplest life forms on our planet, in the course of evolution they have developed ways to communicate efficiently with each other. Unlike humans, their communication is not mediated with words but with chemical signals. This interaction also plays a fundamental role in infection processes of pathogenic bacteria in humans. For example, bacteria…

• 2022-07-12

  Research into antiviral agents

  

  The rapid global spread of the pathogen SARS-CoV-2 has highlighted the importance of having effective drugs available to treat viral diseases. While the spread of SARS-CoV-2 has been mitigated by the rapid development of effective vaccines, this option does not yet exist for many other viruses. In order to research substances for the treatment of such viruses and to develop them for…

• 15.05.2023, 11 am - 16.05.2023, 4 pm - Talk - Scientific

  HDDC 2023

Video

• HIPS Infofilm (English)

  Resistance to antibiotics has become one of the major global challenges regarding infectious diseases. This is specifically the issue that is being tackled by the new Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS).

• How do researchers at the HZI and HIPS develop a new antibiotic?

Audio Podcast

• Kündigung für Biofilm-WGs – Pharmazeuten des HIPS stören BakteriengemeinschaftenBakterien haben einen ausgeprägten Gemeinschaftssinn und verschanzen sich gerne in schleimigen Biofilmen. Etwa 60 Prozent aller bakteriellen Infektionen lösen inzwischen Biofilme aus. Ein besonders geselliger Keim ist Pseudomonas aeruginosa. Er ist besonders für Mukoviszidose-Patienten gefährlich. Wissenschaftler am Helmholtz-Institut für Pharmazeutische Forschung Saarland suchen nach Wegen, seine Biofilme aufzulösen – damit Medikamente wirken können. Begleiten Sie Anke Steinbach in Ihre Labore...